Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency.

Focosi, D; Franchini, M

Focosi, D; Franchini, M.

Focosi D; North-Western Tuscany Blood Bank, Pisa University Hospital, via Paradisa 2, 56124 Pisa, Italy. Electronic address: daniele.focosi@gmail.com.
Franchini M; Department of Hematology and Transfusion Medicine, Carlo Poma Hospital, Mantua, Italy.

Transfus Clin Biol ; 28(2): 132-134, 2021 May.

Article in English | MEDLINE | ID: covidwho-1131858

ABSTRACT

ABSTRACT

Pathogen reduction technologies (PRT) have been recommended by many regulatory authorities to minimize the residual risk of transfusion-transmitted infections associated with COVID19 convalescent plasma. While its impact on safety and its cost-effectiveness are nowadays well proven, there is theoretical concern that PRT could impact efficacy of convalescent plasma by altering concentration and/or function of the neutralizing antibodies (nAb). We review here the evidence supporting a lack of significant detrimental effect from PRTs on nAbs.

Subject(s)

COVID-19/therapy; Infection Control/methods; Transfusion Reaction/prevention & control; Antibodies, Neutralizing/blood; COVID-19/blood; Humans; Immunization, Passive/adverse effects; Treatment Outcome; COVID-19 Serotherapy

Keywords

COVID-19 convalescent plasma; Efficacy; IgG subclasses; Neutralizing antibodies; Pathogen inactivation; Pathogen reduction technologies

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Infection Control / Transfusion Reaction / COVID-19 Type of study: Experimental Studies / Prognostic study Limits: Humans Language: English Journal: Transfus Clin Biol Journal subject: Hematology Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google